CTSA Administrative Supplement for Informatics Core: A novel AI/ML system to predict respiratory failure and ARDS in Covid-19 patients

CTSA 信息学核心行政补充:一种预测 Covid-19 患者呼吸衰竭和 ARDS 的新型 AI/ML 系统

基本信息

  • 批准号:
    10158737
  • 负责人:
  • 金额:
    $ 100.34万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-07-09 至 2021-02-28
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY The Einstein-Montefiore Institute for Clinical and Translational Research (ICTR) proposes an Administrative Supplement pursuant to NOT-TR-20-011, CTSA Program Applications to Address 2019 Novel Coronavirus (Covid-19). Specifically, this application addresses the urgent need for research on the coronavirus pandemic with a project focusing on informatics and data science to preemptively identify patients with the life- threatening complications of SARS-CoV-2, using CTSA-supported core resources. Characterized by severe hypoxemia, tachypnea, and decreased lung compliance, the diagnosis of acute respiratory failure (ARF) is a bad prognostic sign, and in a subset, leads to development of acute respiratory distress syndrome (ARDS). The rates of Covid-19 infection and death in the Bronx have been higher than any other borough of NYC. As the major regional health system, our experience with Covid-19 provides guideposts that may prevent future victims of this pandemic. The bleak picture for ARDS in the 4,452 patients admitted showed that 78% of our intubated Covid-19 patients developed ARDS, with 42% mortality. The overall goal of this proposal is to leverage our novel informatics and analytics platforms enabled by the Einstein-Montefiore CTSA (NIH/NCATS 1ULTR002556), and extensive Artificial Intelligence and Deep Learning resources to implement a novel, situational awareness and clinical decision support system for ARF and ARDS (SA-ARDS). We will re-train our existing deep learning models with data collected from Covid-19 patients and contextualize its implementation with data from the Covid-19 response during the pandemic in NYC. The SA-ARDS data platform will provide longitudinally integrated clinical data for research and multi-institutional and national collaborations, with the following specific aims: Aim 1: To integrate, re-train, and validate our novel, near real-time, Electronic Risk Assessment System (ERAS 1.0) optimized for early recognition of ARF, ARDS, and inpatient mortality; Aim 2: To develop an evidence based, real-time, and context appropriate Situational Awareness clinical decision support system targeting ARF and ARDS response (SA-ARDS); and Aim 3: Through our partner CTSA organizations, to standardize and disseminate ERAS 1.0 and the SA-ARDS to other health systems, including the NYC consortium of CTSA hubs and the PCORI INSIGHT network. We will use the clinical data underlying the SA-ARDS to support research in local, regional, and national collaborations. All the methods and tools developed will be shared with the CTSA community via NCATS' National Center for Data to Health (CD2H).
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MARLA J KELLER其他文献

MARLA J KELLER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MARLA J KELLER', 18)}}的其他基金

Einstein-Montefiore Clinical and Translational Science Award Hub
爱因斯坦-蒙蒂菲奥里临床和转化科学奖中心
  • 批准号:
    10622099
  • 财政年份:
    2023
  • 资助金额:
    $ 100.34万
  • 项目类别:
Convalescent Plasma to Limit Coronavirus Associated Complications: A Randomized Blinded Phase 2 Study Comparing the Efficacy and Safety of Anti-SARS-CoV-2 Plasma to Placebo in COVID-19 hospitalized pa
恢复期血浆限制冠状病毒相关并发症:一项随机盲法 2 期研究,比较抗 SARS-CoV-2 血浆与安慰剂在 COVID-19 住院患者中的功效和安全性
  • 批准号:
    10166008
  • 财政年份:
    2020
  • 资助金额:
    $ 100.34万
  • 项目类别:
Clinical and Translational Science Award
临床和转化科学奖
  • 批准号:
    10112978
  • 财政年份:
    2018
  • 资助金额:
    $ 100.34万
  • 项目类别:
Clinical and Translational Science Award
临床和转化科学奖
  • 批准号:
    9886296
  • 财政年份:
    2018
  • 资助金额:
    $ 100.34万
  • 项目类别:
Clinical and Translational Science Award
临床和转化科学奖
  • 批准号:
    10357784
  • 财政年份:
    2018
  • 资助金额:
    $ 100.34万
  • 项目类别:
Modifies of PrEP Efficacy in US & African Women: Age, Hormones, Sex & Microbiota
美国 PrEP 疗效的修改
  • 批准号:
    8448509
  • 财政年份:
    2013
  • 资助金额:
    $ 100.34万
  • 项目类别:
Safety of Non-Medicated Intravaginal Rings for Microbicide Delivery
用于杀菌剂递送的非药物阴道环的安全性
  • 批准号:
    8012508
  • 财政年份:
    2010
  • 资助金额:
    $ 100.34万
  • 项目类别:
Clinical Study to Measure Pharmacokinetics, Pharmacodynamics and Safety of a TDF
测量 TDF 的药代动力学、药效学和安全性的临床研究
  • 批准号:
    8210597
  • 财政年份:
    2009
  • 资助金额:
    $ 100.34万
  • 项目类别:
EFFECTS OF HORMONES ON MUCOSAL IMMUNE MEDIATORS ACROSS THE MENSTRUAL CYCLE
激素对整个月经周期粘膜免疫介质的影响
  • 批准号:
    7718170
  • 财政年份:
    2008
  • 资助金额:
    $ 100.34万
  • 项目类别:
EFFECTS OF HORMONES ON MUCOSAL IMMUNE MEDIATORS ACROSS THE MENSTRUAL CYCLE
激素对整个月经周期粘膜免疫介质的影响
  • 批准号:
    7605356
  • 财政年份:
    2007
  • 资助金额:
    $ 100.34万
  • 项目类别:

相似海外基金

Optimizing Time-Limited Trials of Mechanical Ventilation in Acute Respiratory Failure: A Mixed Methods Observational Study
优化急性呼吸衰竭机械通气的限时试验:混合方法观察研究
  • 批准号:
    10633823
  • 财政年份:
    2023
  • 资助金额:
    $ 100.34万
  • 项目类别:
Novel Digital Methods to Evaluate Functional and Pulmonary Outcomes following Pediatric Acute Respiratory Failure
评估小儿急性呼吸衰竭后功能和肺部结果的新型数字方法
  • 批准号:
    10724042
  • 财政年份:
    2023
  • 资助金额:
    $ 100.34万
  • 项目类别:
Use of Inter-Hospital Transfer Services in Critical Illness and Acute Respiratory Failure
在危重疾病和急性呼吸衰竭中使用医院间转运服务
  • 批准号:
    10739060
  • 财政年份:
    2023
  • 资助金额:
    $ 100.34万
  • 项目类别:
Strengthening implementation science in Acute Respiratory Failure using multilevel analysis of existing data
利用现有数据的多级分析加强急性呼吸衰竭的实施科学
  • 批准号:
    10731311
  • 财政年份:
    2023
  • 资助金额:
    $ 100.34万
  • 项目类别:
Identifying patient subgroups and processes of care that cause outcome differences following ICU vs. ward triage among patients with acute respiratory failure and sepsis
确定急性呼吸衰竭和脓毒症患者在 ICU 与病房分诊后导致结局差异的患者亚组和护理流程
  • 批准号:
    10734357
  • 财政年份:
    2023
  • 资助金额:
    $ 100.34万
  • 项目类别:
Respiratory Drive in Acute Respiratory Failure
急性呼吸衰竭中的呼吸驱动
  • 批准号:
    10637245
  • 财政年份:
    2023
  • 资助金额:
    $ 100.34万
  • 项目类别:
Health expectations after acute respiratory failure in survivor-care partner dyads
幸存者护理伙伴二人组急性呼吸衰竭后的健康期望
  • 批准号:
    10732929
  • 财政年份:
    2023
  • 资助金额:
    $ 100.34万
  • 项目类别:
Temporal trends in quality indicators of palliative care for patients with chronic illness hospitalized with acute respiratory failure
因急性呼吸衰竭住院的慢性病患者姑息治疗质量指标的时间趋势
  • 批准号:
    10622756
  • 财政年份:
    2023
  • 资助金额:
    $ 100.34万
  • 项目类别:
Financial Hardship among Patients with Acute Respiratory Failure and their Family Member Caregivers: Understanding the Impact on Patient- and Family- Centered Outcomes
急性呼吸衰竭患者及其家庭成员护理人员的经济困难:了解对以患者和家庭为中心的结果的影响
  • 批准号:
    10413457
  • 财政年份:
    2022
  • 资助金额:
    $ 100.34万
  • 项目类别:
Association of patient characteristics and antibiotic timing with the development of acute respiratory failure in hospital-acquired sepsis
患者特征和抗生素使用时机与医院获得性脓毒症急性呼吸衰竭发展的关系
  • 批准号:
    10313769
  • 财政年份:
    2022
  • 资助金额:
    $ 100.34万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了